Replies to post #203739 on Biotech Values

[ghmm]

OCRX:

A couple more very high volume days and no 13D filings. I was part of the high volume :-) (2 days ago on the buy side about 40% increase in position). With the futility analysis/sample size readjustment indicating nearly 2 day benefit seems like a good risk reward here with EV in the ~25M range plus not to mention oral data not too far off (hopefully they have the formulation issues all figured out now).

[DewDiligence]

OCRX clinical updates (STOP-HE almost fully-enrolled):

http://finance.yahoo.com/news/ocera-therapeutics-reports-third-quarter-130500471.html

Enrollment in our STOP-HE Phase 2b study for acute hepatic encephalopathy has now surpassed 220 patients and, consistent with previous guidance, we expect to complete full enrollment of approximately 230 patients by year-end and publish top-line results of the study in the first quarter of 2017,” said Linda Grais, M.D., Chief Executive Officer of Ocera.

“In addition, dosing has commenced with our oral formulation of OCR-002 in a Phase 1 study in patients with cirrhosis as a chronic use option to maintain remission of HE. We remain on track to report results of part one of this study by year-end and initiate part two in the first half of 2017.”